Cargando…

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

OBJECTIVE: In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated the safety and tolerability of anifrolumab using data pooled from these trials to more precisely est...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tummala, Raj, Abreu, Gabriel, Pineda, Lilia, Michaels, M Alex, Kalyani, Rubana N, Furie, Richard A, Morand, Eric F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical Trials and Drug Discovery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893670/ https://www.ncbi.nlm.nih.gov/pubmed/33597205 http://dx.doi.org/10.1136/lupus-2020-000464

Ejemplares similares

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
por: Vital, Edward M, et al.
Publicado: (2022)

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
por: Riggs, Jeffrey M, et al.
Publicado: (2018)

Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study
por: Furie, Richard, et al.
Publicado: (2016)

Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study
por: Furie, Richard A, et al.
Publicado: (2017)

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2021)

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
por: Morand, Eric F, et al.
Publicado: (2023)

Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study
por: Chatham, W. Winn, et al.
Publicado: (2021)

SLE clinical trials: impact of missing data on estimating treatment effects
por: Kim, Mimi, et al.
Publicado: (2019)

Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE
por: Kamen, Diane L, et al.
Publicado: (2022)

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Anifrolumab for systemic lupus erythematosus
Publicado: (2022)

Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis
por: Tian, Jingru, et al.
Publicado: (2018)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
por: Kalunian, Kenneth C., et al.
Publicado: (2022)

Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE)
por: Nasonov, E, et al.
Publicado: (2015)

First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
por: Hermann, Viktoria, et al.
Publicado: (2019)

Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Long-term anifrolumab safe in SLE
por: McHugh, Jessica
Publicado: (2023)

Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2023)

Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study
por: Urowitz, Murray B, et al.
Publicado: (2015)

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2022)

Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort
por: Yap, K S, et al.
Publicado: (2015)

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
por: van Vollenhoven, Ronald F, et al.
Publicado: (2018)

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
por: Jayne, David, et al.
Publicado: (2023)

What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
por: Furie, Richard, et al.
Publicado: (2021)

Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study
por: Jin, Hui-Zhi, et al.
Publicado: (2023)

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
por: Jayne, David, et al.
Publicado: (2022)

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways
por: Dörner, Thomas, et al.
Publicado: (2020)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus
por: Sullivan, B A, et al.
Publicado: (2016)

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA
por: Collins, C E, et al.
Publicado: (2016)

The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness
por: Gracia-Tello, Borja, et al.
Publicado: (2017)

Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials
por: Kim, Mimi, et al.
Publicado: (2018)

Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
por: Arriens, Cristina, et al.
Publicado: (2020)

Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)
por: Dyball, Sarah, et al.
Publicado: (2021)

Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional study
por: Mahran, Safaa A, et al.
Publicado: (2021)

Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study
por: Jiang, Nan, et al.
Publicado: (2022)

Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria for systemic lupus erythematosus: a single-centre retrospective study
por: Lu, Wentian, et al.
Publicado: (2022)

Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials
por: Stull, Donald, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i1umh2j9pjfdo7cjd42o710tfb